What to Look for in a Peptide Telehealth Provider

How to Evaluate Physician Oversight, Compounding Pharmacy Compliance, and Monitoring Standards Before You Commit

If you’ve read any of the compound research overviews on this site — CJC-1295 (no DAC), ipamorelin, BPC-157, semaglutide — you know the pattern. The mechanism is interesting. The human evidence is limited but real. The regulatory status is complicated. And at some point, having done your homework, you find yourself asking the obvious next question: how does someone actually access these compounds legitimately, under physician oversight, in a way that’s safe and legal?

The answer, for most peptides, is telehealth — online platforms that connect patients with licensed physicians who can evaluate, prescribe, and monitor peptide protocols through a virtual care model. Done well, this is genuinely good medicine: accessible, evidence-informed care that most traditional primary care practices simply aren’t equipped to provide. Done badly, it’s a rubber-stamp script mill that hands out prescriptions the way a vending machine hands out snacks, with no meaningful evaluation and no follow-up.

The problem is that from the outside, these two things can look identical. Both have websites that say “board-certified physicians.” Both have intake questionnaires. Both will send you a prescription after a consultation. The difference is in the quality of the medical evaluation, the legitimacy of the compounding pharmacy fulfilling the order, the existence of a monitoring protocol, and whether the provider actually understands peptide pharmacology well enough to catch a problem if one develops.

This guide gives you the criteria to tell the difference. It covers what legitimate peptide prescribing actually looks like, the red flags that identify substandard providers, the questions worth asking before you hand over your credit card, and the compound-specific considerations that apply to the major peptide clusters. The standards described here aren’t invented by Peptidings — they’re derived from what responsible integrative medicine and hormone optimization physicians actually do when they’re practicing carefully.

Why This Question Is Harder Than It Should Be

Peptide telehealth exists in a genuinely complicated regulatory environment, and understanding that environment is prerequisite to evaluating any provider operating within it.

The compounds most commonly sought through telehealth — CJC-1295, ipamorelin, sermorelin, BPC-157, TB-500, semaglutide, tirzepatide, PT-141 — do not follow a single regulatory pathway. Some are FDA-approved drugs being used on-label or off-label. Some are FDA-approved in other formulations but sought as compounded versions. Some are investigational compounds with no approved indication. Some are on the FDA’s Category I list of bulk drug substances eligible for compounding; some are on Category II (not eligible); some are in regulatory limbo pending a final determination.

This matters for evaluating providers because a physician who genuinely understands the regulatory landscape will treat these compounds differently based on their status. A physician who treats them all the same — issuing prescriptions for anything a patient asks for with equal ease — probably doesn’t understand the landscape, or doesn’t care about it, which amounts to the same problem.

The second complicating factor is the compounding pharmacy layer. Virtually every peptide dispensed through telehealth comes from a compounding pharmacy, not a commercial manufacturer. Compounding pharmacies operate under their own regulatory framework — primarily Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act — which governs what they can compound, for whom, and under what oversight conditions. A provider who doesn’t know what pharmacy they use, or who uses a pharmacy with questionable compliance, is a provider whose prescriptions may not reliably contain what they’re supposed to contain at the concentration labeled.

The third factor is the explosive growth of the market. GLP-1 drugs like semaglutide created a surge of investment in online prescribing platforms starting in 2022–2023. Many of these platforms expanded into peptides opportunistically, without building clinical infrastructure appropriate to the compounds. The result is a market where a minority of providers are practicing thoughtfully and a majority are practicing at whatever level the market tolerates.

What Legitimate Peptide Prescribing Actually Looks Like

Before cataloging red flags, it helps to describe the positive case — what a well-run peptide telehealth practice actually does. This description is based on what responsible integrative medicine and functional medicine physicians do when treating patients with peptides as part of a broader health optimization protocol.

The Medical Evaluation Comes First

A legitimate provider treats peptide prescribing as medicine, not as a product transaction. This means the encounter starts with a real intake — not just a health questionnaire, but a conversation with a physician or nurse practitioner who reviews your history, your goals, your medications, and your relevant health conditions. Peptides interact with other medications and underlying conditions in ways that matter clinically. A GH secretagogue protocol in someone with untreated insulin resistance carries different risk considerations than the same protocol in a metabolically healthy person. A provider who doesn’t ask about this isn’t practicing medicine; they’re processing an order.

Baseline Laboratory Work Is Required, Not Optional

Every compound in the major peptide clusters has a set of biomarkers that responsible prescribing requires establishing at baseline. For GH secretagogues: IGF-1 and fasting glucose at minimum, ideally with IGFBP-3 and a fasting insulin. For GLP-1 medications: HbA1c, fasting glucose, lipid panel, kidney function markers. For sexual health peptides: a full hormonal panel appropriate to the patient’s sex. For any protocol involving a person with unknown metabolic health: a comprehensive metabolic panel.

The requirement for baseline labs does two things. First, it identifies contraindications before the prescription is written — an IGF-1 level that is already high-normal before treatment is a reason to start conservatively, not a detail to ignore. Second, it establishes the reference point against which follow-up testing can be compared, so that protocol adjustments are based on data rather than subjective report.

A provider who issues a first prescription without any baseline labs either doesn’t know what to monitor or has decided not to bother. Neither is acceptable.

The Compounding Pharmacy Is Identifiable and Credentialed

A well-run telehealth practice uses compounding pharmacies it has vetted and can name. When you ask which pharmacy fulfills their prescriptions, they tell you. The pharmacy has PCAB (Pharmacy Compounding Accreditation Board) accreditation or equivalent state oversight. The pharmacy provides certificates of analysis (CoA) for each batch, including HPLC purity data and mass spectrometry confirmation of peptide identity. The prescriptions state the concentration explicitly, and the dispensed product includes accurate labeling.

Providers who won’t tell you where the compound comes from — or who use a rotating set of pharmacies without a clear selection rationale — are operating without the quality control layer that responsible compounding requires.

A Monitoring Protocol Exists and Is Followed

Prescribing a peptide protocol and then disappearing is not medicine. A responsible provider builds in follow-up — a check-in at 4–8 weeks to assess early response and side effects, a follow-up laboratory panel at 8–12 weeks to compare against baseline, and an ongoing protocol review cadence as long as the patient continues on the protocol.

Some compounds require more intensive monitoring than others. GH secretagogues that significantly elevate IGF-1 require regular IGF-1 rechecks because sustained supraphysiological IGF-1 carries long-term risk implications. GLP-1 medications require periodic metabolic monitoring. The monitoring schedule is written into the protocol, not left to the patient to arrange independently.

The Six Criteria That Matter

Here is the evaluative framework condensed to its most practical form. These are the six criteria that distinguish a provider worth trusting from one that isn’t, based on what responsible peptide medicine actually requires.

Criterion 1: A Real Medical Consultation With a Qualified Prescriber

The consultation must be conducted by a licensed physician (MD or DO) or nurse practitioner with prescriptive authority in your state. It must involve a real-time conversation — either video or phone — not just a completed questionnaire reviewed asynchronously by someone you never interact with. A questionnaire-only intake is not a medical consultation by any reasonable definition, regardless of how the platform labels it.

The physician should be asking questions, not just answering them. If your “consultation” consists of someone confirming that you’ve filled out the form correctly and informing you your prescription is being processed, you have not received a medical consultation. You have received a transaction.

The prescriber should also be able to tell you what compound they’re prescribing and why — specifically. “CJC-1295 (no DAC) because its pulsatile GH release pattern preserves more natural feedback regulation than the DAC variant” is the kind of specificity that indicates genuine pharmacological understanding. “Our most popular GH protocol” is not.

Criterion 2: Baseline Laboratory Testing Before the First Prescription

This is the single most reliable screening criterion for responsible prescribing. A provider who issues a first prescription for any of the following compounds without baseline lab work is not practicing responsible medicine:

• GH secretagogues (CJC-1295, ipamorelin, sermorelin, tesamorelin, GHRP-2, GHRP-6, hexarelin): IGF-1, fasting glucose, fasting insulin at minimum. IGFBP-3 adds useful context. A comprehensive metabolic panel if not recently obtained.
• GLP-1 medications (semaglutide, tirzepatide, liraglutide): HbA1c, fasting glucose, lipid panel, kidney function (creatinine, eGFR), liver enzymes. Amylase if pancreatitis risk is being assessed. Personal and family history of thyroid cancer is specifically relevant for GLP-1 agents.
• Sexual health peptides (gonadorelin, kisspeptin): Full sex hormone panel — FSH, LH, testosterone (total and free), estradiol, SHBG, prolactin. Thyroid panel if not recently obtained. PSA in males over 40.
• PT-141 (bremelanotide): Blood pressure measurement is specifically relevant given PT-141’s known transient hypertensive effect. Cardiovascular history review.
• BPC-157, TB-500 (where available via compounding): No specific obligatory panel, but a comprehensive metabolic panel and inflammatory markers establish a useful baseline for a compound with claimed tissue repair activity. Liver function is relevant given BPC-157’s mechanism.

Some platforms address the lab requirement by integrating with direct-access lab testing services — they’ll send you to Quest or LabCorp for a required panel before your prescription is issued. This is actually a positive signal: it means they’re building the monitoring requirement into the workflow rather than leaving it as an optional recommendation. Other platforms simply ask “have you had recent bloodwork?” and accept a yes answer without verification. The former is meaningful; the latter is not.

Criterion 3: A Named, Credentialed Compounding Pharmacy

The compounding pharmacy is not a background detail — it’s where the quality control either happens or doesn’t. A provider who won’t tell you which pharmacy they use is a provider you shouldn’t trust, because you have no way to verify what you’re receiving.

What to look for in the pharmacy itself:

• PCAB accreditation: The Pharmacy Compounding Accreditation Board sets standards that exceed FDA minimum requirements. PCAB-accredited pharmacies are publicly listed and have undergone independent audit. This is the gold standard for compounding pharmacy credentialing.
• 503A vs. 503B status: 503A pharmacies compound patient-specific prescriptions on a one-off basis. 503B “outsourcing facilities” can produce larger batches under enhanced FDA oversight. For individual patient prescriptions, 503A is the appropriate model. What matters is that the pharmacy operates under one of these clearly defined frameworks — not in some unaccredited grey zone.
• Certificate of Analysis availability: A quality compounding pharmacy provides a CoA for each lot of compounded product, showing HPLC purity data and mass spectrometry confirmation. Some platforms will share the CoA on request; responsible ones provide it proactively. If a provider says their pharmacy doesn’t provide CoAs, walk away.
• State licensure: The compounding pharmacy must be licensed to ship to your state. Shipping compounded medications across state lines without proper licensure creates legal exposure for both the pharmacy and the patient.

Criterion 4: A Written Protocol With Specific Dosing Parameters

After the consultation, you should receive a written protocol. Not a verbal summary. A written document that specifies: the compound, the concentration of the compounded preparation, the dose, the frequency, the administration route, the duration of the initial protocol, the timing of follow-up assessment, and what to do if you experience specific side effects.

The dose should be a specific number with a specific rationale — not a range handed over with the instruction to “see how you feel.” Peptide dosing in the published literature follows specific patterns, and a provider who understands that literature can explain why a particular dose was chosen. See our individual compound research overviews for the dosing ranges documented in published studies — if a provider’s prescription falls significantly outside published ranges without explanation, ask why.

Criterion 5: A Scheduled Follow-Up and Monitoring Plan

The follow-up cadence should be built into the protocol from the start, not left as an open-ended “let us know if you have questions.” Specifically:

• Early check-in (4–6 weeks): To assess early response, identify side effects, and make initial adjustments. This can be asynchronous — a provider message or portal check-in — but it needs to happen.
• Follow-up labs (8–12 weeks): To compare against baseline and verify the protocol is producing the intended physiological changes without adverse ones. For GH secretagogues, this means an IGF-1 recheck. For GLP-1 medications, metabolic markers. For hormonal protocols, the relevant panel.
• Protocol review (3–6 months): A structured reassessment of whether the protocol is meeting its goals and whether continuation is appropriate.

A provider whose model is to issue a prescription and then wait for the patient to contact them for refills is not providing monitoring — they’re providing dispensing. The distinction matters clinically.

Criterion 6: They Will Tell You What They Won’t Prescribe, and Why

This criterion is counterintuitive but important. A provider who will prescribe anything you ask for is not a better provider than one who pushes back on certain requests — they’re a worse one. Legitimate medical practice includes saying no when the evidence doesn’t support a protocol, when regulatory status makes prescription inappropriate, or when a patient’s individual health profile creates unacceptable risk.

Concretely: a provider who is comfortable prescribing CJC-1295 (no DAC) for growth hormone optimization but who declines to prescribe Melanotan II (an unregistered, non-FDA-approved melanocortin agonist with significant cardiovascular and other safety concerns) is exercising clinical judgment. A provider who will prescribe both with equal ease has either done no risk differentiation or has decided risk differentiation is bad for business. Neither is reassuring.

Ask a prospective provider about their limits. Ask them what compounds they won’t prescribe and why. A thoughtful answer to this question is a strong positive signal. Discomfort with the question, or an answer suggesting they’ll prescribe anything legally available, is a negative one.

Red Flags: A Field Guide

The following patterns, individually or in combination, indicate a provider whose practice standards are below what responsible prescribing requires. Some are disqualifying on their own; others become disqualifying when they cluster.

Questions to Ask Before You Commit

The following questions are worth asking during or before an initial consultation. Good providers will welcome them. Providers who become evasive, dismissive, or annoyed when asked these questions are telling you something important.

About the Consultation Process

• “Will I have a live conversation with the prescribing physician before any prescription is issued — not just a questionnaire review?”
• “What is the physician’s background specifically relevant to hormone optimization or peptide therapy?”
• “Can I verify the prescribing physician’s license on my state’s licensing board?”
• “If I have follow-up questions after the consultation, how do I reach the physician — not a coordinator?”

About Laboratory Testing

• “What baseline labs do you require before issuing a first prescription for [specific compound]?”
• “What labs will you want me to repeat, and at what interval, once I’m on the protocol?”
• “Do you have a preferred lab service, or do I arrange my own testing?”
• “What lab result would cause you to modify or stop the protocol?”

About the Compounding Pharmacy

• “Which compounding pharmacy fulfills your prescriptions?”
• “Is that pharmacy PCAB-accredited?”
• “Can I get a Certificate of Analysis for the lot that will be dispensed to me?”
• “Is that pharmacy licensed to ship to [your state]?”
• “What is the peptide’s listed concentration on the label, and does the CoA confirm that concentration?”

About the Protocol Itself

• “What is the rationale for the specific dose you’re recommending, and how does it relate to published research?”
• “What are the most common side effects I should watch for, and what should I do if I experience them?”
• “What is the planned duration of the initial protocol before we reassess?”
• “Are there any medications or supplements I’m currently taking that interact with this compound?”
• “What is your position on the regulatory status of this compound — specifically, is it on the FDA’s Category I eligible-for-compounding list?”

About Their Limits

• “Are there peptide compounds you won’t prescribe? Which ones and why?”
• “What would cause you to decline to prescribe this compound for a specific patient?”
• “If my IGF-1 comes back elevated at the follow-up, what happens next?”

The First Consultation: What to Expect and What to Watch For

A well-run first consultation with a peptide telehealth provider follows a recognizable structure. Understanding what that structure looks like helps you evaluate whether what you’re experiencing is legitimate.

Before the Consultation

You should receive — and be asked to complete — a comprehensive intake questionnaire covering your medical history, current medications and supplements, relevant symptoms and health goals, and prior experience with any similar compounds or treatments. Some platforms send you to complete baseline labs before the consultation; others will conduct the consultation and then require labs before issuing the prescription. Either sequence is acceptable; skipping labs entirely is not.

During the Consultation

The consultation should last at least 20–30 minutes for an initial visit — enough time to review your history meaningfully, address your goals, explain the proposed protocol, cover side effects and monitoring, and answer questions. A consultation that runs 5–10 minutes has not provided adequate time for any of these. Note: some platforms use a two-step model where a coordinator does an initial intake and then a physician reviews and calls back — this can work if the physician genuinely reviews the case thoroughly, but the physician conversation must happen.

During the conversation, the physician should be demonstrating clinical knowledge — explaining the mechanism of the proposed compound, describing the evidence base accurately (including its limitations), and asking questions that would only matter clinically. If the physician’s contribution to the conversation is primarily confirming your stated preferences and reviewing your credit card information, the consultation is not clinical in any meaningful sense.

After the Consultation

After the consultation, you should receive documentation. At minimum: a care summary confirming the proposed protocol, the lab orders or instructions for obtaining required labs, and contact information for follow-up questions. The prescription itself should specify the compound name, concentration (mcg/mL as compounded), dose, frequency, administration route, quantity, and refills. Any ambiguity in these specifications is a problem — reconstitution and dosing errors often trace back to prescriptions that didn’t specify concentration clearly.

State-by-State Access Reality

Telehealth prescribing in the United States is regulated at the state level. A physician must be licensed in the state where the patient is located at the time of the consultation in order to legally prescribe to that patient. This rule is largely consistent across states, though the details of telehealth-specific prescribing regulations vary.

What this means practically:

• Multi-state licensed providers are necessary for national coverage. Telehealth platforms serving patients across the country must have physicians licensed in every state they operate in. Some platforms explicitly state which states they serve. If yours isn’t listed, verify before completing an intake.
• Compounding pharmacy licensure must also match. A compounding pharmacy licensed in California can ship to a California patient, but may not be licensed to ship to Texas. Both the prescribing physician and the dispensing pharmacy must be operating within your state’s regulatory framework.
• Certain states have additional restrictions. New York, New Jersey, and Rhode Island have historically had more restrictive telemedicine frameworks. A handful of states restrict certain categories of compounded medications specifically. This landscape changes as telemedicine regulations evolve.
• The Ryan Haight Act for controlled substances. Compounds that are controlled substances (some hormonal medications, not most peptides) face additional federal restrictions on telemedicine prescribing. Most research peptides are not controlled substances, but verify this for any compound with a scheduled status.

A reputable provider will screen your location at intake and tell you if they can’t serve your state. A provider who takes your payment without flagging a potential access issue is either not checking or not being forthcoming — neither is a good sign.

What You’re Actually Paying For

Peptide telehealth is not cheap, and that’s not accidental. Understanding what the cost covers helps you evaluate pricing rationally rather than gravitating toward the cheapest option — which, in compounded medications dispensed under physician supervision, is often the most dangerous option.

The Cost Components

A typical peptide telehealth protocol involves several cost layers:

• Initial consultation fee: Typically $150–$400 for the initial physician visit. This covers the physician’s time for a thorough evaluation. Platforms that charge $0–$50 for the initial consultation are almost certainly subsidizing it through inflated product pricing or thin medical oversight.
• Laboratory testing: Baseline labs at a commercial lab (Quest, LabCorp) run $100–$400 depending on the panel ordered. Some platforms integrate lab costs into their service fee; others require you to order independently. Either model is fine — the requirement to test at all is what matters.
• Compounded medication: The cost of the compounded peptide itself. A quality compounding pharmacy charges significantly more than a grey-market vendor because they’re running HPLC, performing identity verification, maintaining sterile conditions, and providing batch CoAs. Prices that seem impossibly low relative to market rates warrant skepticism about quality.
• Ongoing management fee or subscription: Many platforms charge a monthly or quarterly fee for ongoing access to physician messaging, protocol adjustments, and monitoring. This should be explicitly stated upfront, not discovered after the initial purchase.

What Corners-Cut Pricing Actually Means

When a peptide telehealth platform charges materially less than its competitors for the same compounds, the cost reduction has to come from somewhere. The realistic options are: thinner physician consultation time (faster throughput, lower quality evaluation), cheaper compounding pharmacy (lower quality control), no genuine monitoring infrastructure, or some combination. There is no version of this where the patient gets the same quality of care for significantly less money. The economics don’t allow it.

This is not an argument that expensive is automatically better — premium pricing can also reflect marketing spend rather than clinical quality. But pricing that falls significantly below market should prompt specific questions about where the cost reduction is coming from.

Compound-Specific Considerations by Cluster

The general criteria above apply to all peptide telehealth. The following cluster-specific notes address the particular considerations that apply when evaluating providers for specific research clusters.

Growth Hormone Secretagogues (CJC-1295, Ipamorelin, Sermorelin, Tesamorelin)

GH secretagogues are among the most commonly sought peptides through telehealth and, accordingly, attract the highest concentration of substandard providers. The specific considerations:

IGF-1 monitoring is non-negotiable. GH secretagogues work by stimulating endogenous growth hormone release, which raises IGF-1. The clinical concern with sustained GH secretagogue use is that chronically elevated IGF-1 — supraphysiological IGF-1 — has associations with certain malignancies, particularly prostate and colon cancer. This is not a reason to avoid these compounds; it’s a reason to monitor. A provider who doesn’t check IGF-1 at baseline and on-protocol is not providing medically appropriate oversight.

Ask specifically about CJC-1295 with vs. without DAC. The DAC (Drug Affinity Complex) variant of CJC-1295 creates a very long-acting GH pulse profile — weeks rather than hours — which some physicians consider more physiologically disruptive than the pulsatile pattern produced by the no-DAC version. A provider who understands this distinction and can articulate their preference and rationale demonstrates genuine pharmacological knowledge. A provider who calls both “CJC-1295” interchangeably does not. See the full comparison in our CJC-1295 (no DAC) and CJC-1295 (with DAC) overviews.

MK-677 is not a peptide and is not prescribed by the same mechanism. Ibutamoren (MK-677) is a non-peptide ghrelin mimetic — a small molecule, not a peptide — that some providers bundle with peptide protocols. Its regulatory status and safety profile differ from GH secretagogue peptides. A provider who substitutes MK-677 for a GH secretagogue peptide without explaining the distinction, or who bundles them together without pharmacological rationale, may not fully understand what they’re prescribing. See our MK-677 research overview for the distinction.

Fasting glucose and insulin monitoring is relevant. GH elevation causes insulin resistance — this is a known and documented effect. A patient with pre-existing insulin resistance or metabolic syndrome who initiates a GH secretagogue protocol without baseline and follow-up glucose monitoring is being managed without appropriate metabolic oversight.

GLP-1 Weight Loss Medications (Semaglutide, Tirzepatide, Liraglutide)

GLP-1 medications represent the highest-volume category in the peptide telehealth market and the category with the most active regulatory situation. The specific considerations:

Compounding status has been in flux. The FDA’s compounding eligibility for semaglutide and tirzepatide has been contested. During shortage periods, compounding was eligible; as branded supply normalized, the FDA began restricting compounding. Any provider dispensing compounded semaglutide or tirzepatide in 2025 and beyond should be able to articulate the current regulatory status and why their prescribing practice is compliant. “We’ve always done it this way” is not a satisfactory answer to a question about current regulatory compliance.

Cardiovascular and renal evaluation is required. GLP-1 medications are contraindicated in patients with certain cardiovascular conditions and require monitoring for kidney function changes. A cursory questionnaire is not an adequate evaluation — a real consultation should cover relevant history and establish that the patient is an appropriate candidate. See our semaglutide and tirzepatide research overviews for the full clinical picture.

Pancreatitis risk requires specific history-taking. GLP-1 medications have been associated with pancreatitis in postmarketing surveillance. A history of pancreatitis or high-risk alcohol use is a relevant contraindication that a proper intake should be capturing.

The stacking problem applies here. Some providers offer protocols that combine multiple GLP-1 agents (e.g., tirzepatide + retatrutide) or combine GLP-1 agents with other metabolic compounds in ways that create pharmacological redundancy without additional clinical benefit. Our More Is Not Always More guide covers the pharmacological case analysis.

Sexual Health and Hormonal Peptides (PT-141, Gonadorelin, Kisspeptin)

PT-141 (bremelanotide) is an FDA-approved drug — marketed as Vyleesi for hypoactive sexual desire disorder in premenopausal women. A provider prescribing it off-label (for men, or for other indications) should be able to clearly articulate the off-label rationale and document that appropriate informed consent has been obtained. Blood pressure evaluation is specifically relevant given PT-141’s transient hypertensive effect; the FDA label includes a contraindication for patients with cardiovascular or cerebrovascular disease. See the full overview at our PT-141 research page.

Gonadorelin protocols require understanding of HPG axis physiology. Gonadorelin is used primarily as a pulsatile LH/FSH stimulator in patients on TRT (testosterone replacement therapy) to maintain testicular function, or as a fertility-supporting agent. A provider prescribing gonadorelin without understanding the pulsatile dosing requirement — gonadorelin must be dosed at intervals that mimic endogenous GnRH pulsatility or it achieves the opposite of the intended effect through receptor downregulation — has a fundamental knowledge gap. See our gonadorelin research overview for the full pharmacology.

Hormonal baseline labs are essential. Sexual health and hormonal peptides act on a complex axis where small changes produce downstream effects that may not be apparent for weeks or months. Baseline FSH, LH, testosterone, estradiol, SHBG, and prolactin are the minimum for any protocol touching the HPG axis. A provider who doesn’t order these isn’t managing the patient’s hormonal health — they’re modifying it blindly.

Injury Recovery Peptides (BPC-157, TB-500)

BPC-157 and TB-500 occupy an unusual regulatory position. Both have meaningful preclinical evidence bases and are widely sought in the self-experimentation community. Neither is FDA-approved for any indication, and their compounding status has been subject to FDA review. The specific considerations for evaluating providers:

Honest regulatory disclosure is a green flag. A provider who says “BPC-157 is a preclinical compound with no approved indication — we’re prescribing it off-label as a compounded medication under our clinical judgment, and you should understand what that means” is more trustworthy than one who presents it as a mainstream treatment. The honest framing demonstrates both knowledge and integrity.

BPC-157 compounding status requires current verification. The FDA’s position on BPC-157 compounding eligibility has been actively reviewed. Providers should be checking current status, not relying on what was permissible in 2022. As of 2025, the landscape had shifted sufficiently that providers offering BPC-157 via compounding should be prepared to explain their compliance rationale specifically.

Systemic vs. targeted administration. A sophisticated provider distinguishes between oral BPC-157 (for GI applications), systemic subcutaneous injection (for systemic tissue repair claims), and targeted subcutaneous injection near the injury site. These routes have different evidence bases and different risk profiles. A one-size-fits-all protocol without route rationale is a sign that the provider hasn’t thought through the delivery question carefully.

See our full research overviews: BPC-157 and TB-500.

Hair Loss Treatments (Finasteride, Dutasteride, Minoxidil via Telehealth)

Hair loss telehealth is the most crowded segment of the market, with the widest range of provider quality. The compounds here are different from most peptide clusters — finasteride and dutasteride are approved drugs, minoxidil is available OTC — but the evaluation criteria are the same.

Hormonal context matters for AGA. Androgenetic alopecia (AGA) is driven by DHT — the downstream conversion product of testosterone. Understanding a patient’s hormonal profile before prescribing a 5-alpha-reductase inhibitor (finasteride, dutasteride) is relevant clinical practice. DHT and testosterone levels provide context for treatment selection and response prediction.

Finasteride’s psychiatric side effect profile requires disclosure. Post-finasteride syndrome — persistent sexual, cognitive, and psychological symptoms following finasteride discontinuation — is a documented and contested phenomenon with an active 2025 literature. A provider prescribing finasteride should be proactively disclosing this risk profile and documenting that the patient understands it, not mentioning it only if asked.

Customized compounded formulas require specific justification. Some hair telehealth platforms offer customized topical formulas combining finasteride, minoxidil, retinoic acid, and other agents at non-standard concentrations. This can be clinically appropriate — personalized combination therapy is a real concept in dermatology — but “customized” should mean “tailored to your specific clinical profile,” not “our proprietary formula we apply to everyone.”

For the peptide compounds specifically relevant to hair — PTD-DBM, biotinoyl tripeptide-1, copper peptides — see the full Hair & Follicle research cluster. These compounds are not typically dispensed through conventional telehealth, but the same evaluation criteria apply to any platform offering them.

After the First Prescription: Evaluating Your Provider Ongoing

The initial evaluation screens for disqualifying problems. Ongoing evaluation — assessing your provider’s performance after the relationship has begun — catches the subtler issues that only become apparent over time.

Positive Signals to Look For

• Follow-up labs are ordered on schedule and reviewed with you, not just noted in your file
• Protocol adjustments are made based on lab results and symptom report, not just renewed automatically
• The physician is reachable when you have a clinical question — not just a coordinator who forwards messages
• When you report a side effect, the response is a clinical evaluation, not a reassurance that “this is normal”
• The provider stays current on regulatory developments affecting your compounds and communicates them to you proactively
• At protocol review, there is a genuine reassessment of whether continuation is appropriate — not an automatic renewal

Reasons to Reevaluate or Transition Away

• Follow-up labs are never ordered despite protocol commitments
• Lab results outside normal range are acknowledged but not acted on
• The provider changes compounding pharmacies without explaining why or providing updated CoA documentation
• Reported side effects are minimized or dismissed rather than evaluated
• Regulatory changes affecting your compounds occur and the provider doesn’t address them
• Refills are processed without any meaningful assessment of whether the protocol is working or appropriate to continue

Transitioning between telehealth providers mid-protocol is disruptive but not complicated. Your medical records — including lab results and prescription history — are yours and are transferable. A new provider who has that history can pick up the protocol with continuity. The disruption of switching is considerably less costly than the risk of continuing with a provider who isn’t monitoring appropriately.